225 related articles for article (PubMed ID: 16462498)
41. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
42. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
[TBL] [Abstract][Full Text] [Related]
43. Auditing a new lung cancer service.
Cullen JP; Glynn C; Murtagh E; Hogan B; Jeffers M; Lane SJ
Ir Med J; 2004 Oct; 97(9):281-3. PubMed ID: 15568588
[TBL] [Abstract][Full Text] [Related]
44. Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy.
Bischof M; Debus J; Herfarth K; Muley T; Kappes J; Storz K; Hoffmann H
Strahlenther Onkol; 2007 Dec; 183(12):679-84. PubMed ID: 18040612
[TBL] [Abstract][Full Text] [Related]
45. Raised serum urea predicts for early death in small cell lung cancer.
Winter MC; Potter VA; Woll PJ
Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):745-50. PubMed ID: 18845424
[TBL] [Abstract][Full Text] [Related]
46. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.
Kim YH; Goto K; Yoh K; Niho S; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
Cancer; 2008 Nov; 113(9):2518-23. PubMed ID: 18780323
[TBL] [Abstract][Full Text] [Related]
47. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
48. Practical issues in the management of the patient with small cell lung cancer.
Govindan R; Ihde DC
Chest Surg Clin N Am; 1997 Feb; 7(1):167-81. PubMed ID: 9001763
[TBL] [Abstract][Full Text] [Related]
49. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer.
Watkins JM; Wahlquist AE; Shirai K; Garrett-Mayer E; Aguero EG; Fortney JA; Sherman CA; Sharma AK
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1108-13. PubMed ID: 19084345
[TBL] [Abstract][Full Text] [Related]
50. Small cell lung cancer: patterns of care and their influence on survival - 25 years experience of a single Australian oncology unit.
Bishnoi S; Pittman K; Colbeck M; Townsend A; Hardingham J; Sukumaran S; Hooper B; Tuck M; Roder D; Luke C; Price T
Asia Pac J Clin Oncol; 2011 Sep; 7(3):252-7. PubMed ID: 21884436
[TBL] [Abstract][Full Text] [Related]
51. Time factor in radiotherapy and chemotherapy for limited disease small-cell lung cancer.
Nowara E; Suwinski R
Cancer Invest; 2007; 25(3):163-71. PubMed ID: 17530486
[TBL] [Abstract][Full Text] [Related]
52. Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998-2004.
Hallqvist A; Rylander H; Björk-Eriksson T; Nyman J
Acta Oncol; 2007; 46(7):969-74. PubMed ID: 17851846
[TBL] [Abstract][Full Text] [Related]
53. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
54. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
55. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis.
Ballonoff A; Rusthoven KE; Schwer A; McCammon R; Kavanagh B; Bassetti M; Newman F; Rabinovitch R
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1465-71. PubMed ID: 18495371
[TBL] [Abstract][Full Text] [Related]
56. Concurrent chemoradiotherapy for limited-disease small cell lung cancer in elderly patients aged 75 years or older.
Shimizu T; Sekine I; Sumi M; Ito Y; Yamada K; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
Jpn J Clin Oncol; 2007 Mar; 37(3):181-5. PubMed ID: 17426103
[TBL] [Abstract][Full Text] [Related]
57. [Clinical features and prognosis of multiple primary tumors of lung combined with other organs--report of 281 cases].
Yi SZ; Zhang DC; Wang YG; Sun KL
Ai Zheng; 2006 Jun; 25(6):731-5. PubMed ID: 16764770
[TBL] [Abstract][Full Text] [Related]
58. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
[TBL] [Abstract][Full Text] [Related]
59. [Small cell lung carcinoma].
Pujol JL; Quantin X; Jacot W; Boher JM; Molinier O; Godard P
Rev Prat; 2003 Apr; 53(7):735-42. PubMed ID: 12879796
[TBL] [Abstract][Full Text] [Related]
60. Long-term results of prophylactic cranial irradiation for limited-stage small-cell lung cancer in complete remission.
Cao KJ; Huang HY; Tu MC; Pan GY
Chin Med J (Engl); 2005 Aug; 118(15):1258-62. PubMed ID: 16117878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
